Enhanced Chondrogenic Differentiation Activities in Human Bone Marrow Aspirates via
SOX9
cartilage repair
chondrogenesis
human bone marrow aspirates
pNaSS-grafted PCL films
rAAV
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
21 Mar 2020
21 Mar 2020
Historique:
received:
15
01
2020
revised:
13
03
2020
accepted:
19
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
5
4
2020
Statut:
epublish
Résumé
The delivery of therapeutic genes in sites of articular cartilage lesions using non-invasive, scaffold-guided gene therapy procedures is a promising approach to stimulate cartilage repair while protecting the cargos from detrimental immune responses, particularly when targeting chondroreparative bone marrow-derived mesenchymal stromal cells in a natural microenvironment like marrow aspirates. Here, we evaluated the benefits of providing a sequence for the cartilage-specific sex-determining region Y-type high-mobility group box 9 (SOX9) transcription factor to human marrow aspirates via recombinant adeno-associated virus (rAAV) vectors delivered by poly(ε-caprolactone) (PCL) films functionalized via grafting with poly(sodium styrene sulfonate) (pNaSS) to enhance the marrow chondrogenic potential over time. Effective These findings show the benefits of targeting patients' bone marrow via PCL film-guided therapeutic rAAV (
Sections du résumé
BACKGROUND
BACKGROUND
The delivery of therapeutic genes in sites of articular cartilage lesions using non-invasive, scaffold-guided gene therapy procedures is a promising approach to stimulate cartilage repair while protecting the cargos from detrimental immune responses, particularly when targeting chondroreparative bone marrow-derived mesenchymal stromal cells in a natural microenvironment like marrow aspirates.
METHODS
METHODS
Here, we evaluated the benefits of providing a sequence for the cartilage-specific sex-determining region Y-type high-mobility group box 9 (SOX9) transcription factor to human marrow aspirates via recombinant adeno-associated virus (rAAV) vectors delivered by poly(ε-caprolactone) (PCL) films functionalized via grafting with poly(sodium styrene sulfonate) (pNaSS) to enhance the marrow chondrogenic potential over time.
RESULTS
RESULTS
Effective
CONCLUSIONS
CONCLUSIONS
These findings show the benefits of targeting patients' bone marrow via PCL film-guided therapeutic rAAV (
Identifiants
pubmed: 32245159
pii: pharmaceutics12030280
doi: 10.3390/pharmaceutics12030280
pmc: PMC7151167
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : DFG VE 1099/1-1
Organisme : University Paris 13, Sorbonne Paris Cité
ID : University Paris 13, Sorbonne Paris Cité
Références
N Engl J Med. 1994 Oct 6;331(14):889-95
pubmed: 8078550
J Orthop Sports Phys Ther. 1998 Oct;28(4):192-202
pubmed: 9785255
Nat Rev Rheumatol. 2019 Jan;15(1):18-29
pubmed: 30514957
Nat Genet. 1999 May;22(1):85-9
pubmed: 10319868
ACS Appl Mater Interfaces. 2017 Jan 18;9(2):1361-1372
pubmed: 28005327
J Mater Sci Mater Med. 2015 Jul;26(7):206
pubmed: 26155977
J Virol. 1989 Sep;63(9):3822-8
pubmed: 2547998
Tissue Eng Part A. 2011 Aug;17(15-16):1969-78
pubmed: 21449684
J Mol Med (Berl). 2013 May;91(5):625-36
pubmed: 23149825
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4513-22
pubmed: 27432980
J Clin Immunol. 2004 Mar;24(2):162-9
pubmed: 15024183
Int J Pharm. 2017 Oct 15;531(2):492-503
pubmed: 28552768
Hum Gene Ther. 2018 Nov;29(11):1277-1286
pubmed: 29717624
Exp Cell Res. 1998 Jan 10;238(1):265-72
pubmed: 9457080
Acta Biomater. 2015 May;18:118-27
pubmed: 25712390
Genes Dev. 2004 May 1;18(9):1072-87
pubmed: 15132997
Biomaterials. 2011 Jul;32(19):4385-92
pubmed: 21421267
J Bone Joint Surg Am. 1998 Dec;80(12):1795-812
pubmed: 9875939
Dtsch Arztebl Int. 2011 Oct;108(40):669-77
pubmed: 22114626
Arthritis Rheum. 2007 Jan;56(1):158-67
pubmed: 17195218
J Virol. 1987 Oct;61(10):3096-101
pubmed: 3041032
Genes Dev. 2002 Nov 1;16(21):2813-28
pubmed: 12414734
Curr Top Dev Biol. 2019;133:171-193
pubmed: 30902252
Gene Ther. 2015 Jan;22(1):50-7
pubmed: 25338919
J Orthop Res. 2019 Aug;37(8):1671-1680
pubmed: 31042304
Int J Nanomedicine. 2017 Sep 19;12:6985-6996
pubmed: 29033566
Tissue Eng Part A. 2010 Apr;16(4):1291-301
pubmed: 19903085
Tissue Eng Part A. 2009 Sep;15(9):2687-98
pubmed: 19216641
Int J Pharm. 2015 Dec 30;496(2):614-26
pubmed: 26556623
Discov Med. 2016 Jun;21(118):495-506
pubmed: 27448786
Acta Biomater. 2015 Nov;27:42-52
pubmed: 26320543
Tissue Eng Part A. 2020 Apr;26(7-8):450-459
pubmed: 31680637
Tissue Eng Part A. 2016 May;22(9-10):776-87
pubmed: 27079852
Nat Genet. 1997 Jun;16(2):174-8
pubmed: 9171829
Biomaterials. 2014 Jul;35(22):5921-31
pubmed: 24767790
Acta Biomater. 2014 Oct;10(10):4103-12
pubmed: 24854956
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
J Control Release. 2012 Feb 28;158(1):15-33
pubmed: 21963774
Transplant Proc. 2006 Jan-Feb;38(1):318-9
pubmed: 16504736
ACS Appl Mater Interfaces. 2016 Aug 17;8(32):20600-13
pubmed: 27404480
Discov Med. 2018 Apr;25(138):195-203
pubmed: 29723490
Biomaterials. 2018 Sep;177:161-175
pubmed: 29894913
Acta Biomater. 2017 Nov;63:210-226
pubmed: 28899816
Tissue Eng. 1998 Winter;4(4):415-28
pubmed: 9916173
J Biomed Mater Res A. 2013 Nov;101(11):3097-108
pubmed: 23529956
Arthrosc Tech. 2012 Sep 14;1(2):e175-80
pubmed: 23766992
J Biol Chem. 2000 Apr 14;275(15):10738-44
pubmed: 10753864
Mol Pharm. 2018 Jul 2;15(7):2816-2826
pubmed: 29763553
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):E798-806
pubmed: 24550481
Mater Sci Eng C Mater Biol Appl. 2014 Dec;45:620-34
pubmed: 25491872
Adv Mater. 2020 Jan;32(2):e1906508
pubmed: 31763733